Scientific Articles COVID-19 articles

Recomendaciones de la ACC con el nuevo coronavirus

Anosmia 1 Year After a COVID-19 Diagnosis

Anosmia 1 Year After a COVID-19 Diagnosis

The number of people with post-COVID-19 syndrome seems to be growing exponentially, so we need long-term data to help physicians advise patients correctly. Among the many persistent symptoms, post-COVID-19 anosmia has good prognosis and almost full recovery at 1 year. In April, 2020, these same authors published a cohort of almost 100 COVID-19 positive patients (positive

indicación de tratamiento con estatinas

Could Statins Do More than Lower Cholesterol in COVID-19 Patients?

A history of acute myocardial Infarction, cardiac failure or hyperlipidemia has been associated with increased mortality of COVID-19. Observational studies have suggested statins might reduce death risk from COVID-19, in addition to lowering cholesterol.  Statins have anti-inflammatory and antithrombotic effects that could play a role in the course of the infection.  Other studies have arrived

Síntomas persistentes post COVID-19: mucho más frecuentes de lo que creíamos

Efficacy of the Novavax Vaccine Against COVID-19: Nanoparticle Technology to the Test

In healthy adults, two doses of the NVX-CoV2373 (Novavax) vaccine has an efficacy of almost 90% against SARS-CoV-2 infection in all severity types. Furthermore, it has proven to be effective against the alpha variant (B.1.1.7). The Novavax vaccine is a recombinant nanoparticle containing full-length spike glycoprotein. It had already been shown to be safe and

Recomendaciones de la ACC con el nuevo coronavirus

Janssen: Efficacy of the Only Single Dose Vaccine against COVID-19

One single dose of the Ad26.COV2.S vaccine (Janssen) will protect you against symptomatic and asymptomatic SARS-CoV-2 infection. It also resulted effective to prevent severe or critical COVID-19, including hospitalization and death. Safety outcomes resulted similar to other COVID-19 vaccine phase 3 outcomes. Janssen vaccine outcomes were published in NEJM 6 months after the first vaccines

Síntomas persistentes post COVID-19: mucho más frecuentes de lo que creíamos

Myocarditis and mRNA COVID-19 Vaccines: New Information from the CDC

According to the CDC (Center for Disease Control and Prevention), even though rare, a relationship between myocarditis and mRNA COVID-19 Vaccines definitely exists. Such risk is more prevalent among men, teenagers and young adults a few days following the second dose.  Globally, the risk is low: 4.4 of cases per million after the first dose

Síntomas persistentes post COVID-19: mucho más frecuentes de lo que creíamos

Post COVID-19 Persistent Symptoms: Far More Common than Expected

After the acute phase of COVID-19 infection, we commonly observe persistent symptoms that can alter functionality and quality of life.  Persistent symptoms are those that continue at least 60 days after diagnosis or at least 30 days after recovery from the acute phase, or after discharge.  Many of the studies included in this review have

Historia natural de la infección asintomática por COVID-19

Efficacy of the Sinopharm Vaccine Against COVID-19

Vaccines developed with two different inactivated strains of SARS-CoV-2 (Sinopharm) significantly reduced the risk of symptomatic cases of COVID-19 with an excellent safety profile. Its proven technology—already used against other virus (influenza, hepatitis, polio, rabies)—and the fact that they can be stored at 2-8 °C mean that they are easily (and cheaply) produced, stored, and administered.

Recomendaciones de la ACC con el nuevo coronavirus

COVID-19 Risk in Vaccinated Healthcare Workers

Vaccinated healthcare workers have a risk of being infected with SARS-CoV-2 of about 1%, a rate that is much higher than that reported in clinical studies. Multiple reasons can explain this difference. However, emphasis should be placed on the paramount importance of protective measures, such as wearing a facemask, social distancing, daily symptom checking, and

Es posible esterilizar las máscaras N95 y los barbijos quirúrgicos

Primary COVID-19 Infection Protects Against Potential Reinfection?

These study outcomes suggest reinfection is relatively rare in patients who recover from COVID-19. In addition, natural immunity against SARS-CoV-2 persists for at least one year and offers similar protection to that reported by vaccines.   These data were obtained from cases infected with the original virus. For now, we do not know if it also

Historia natural de la infección asintomática por COVID-19

Myocarditis and Messenger RNA COVID-19 Vaccine: What Is the Risk?

European and American agencies (such as the Centers for Disease Control [CDC]) have begun evaluating reports on myocarditis in individuals who received one of the COVID-19 vaccines based on messenger RNA technology (Pfizer/BioNTech and Moderna). This possible association has not been yet established and, even if confirmed in the future, it would not undermine the

Resultados de la vacuna de Pfizer/BioNTech contra el COVID-19 en adolescentes

Pfizer/BioNTech Vaccine against COVID-19 in Teenagers

COVID-19 vaccine developed by Pfizer/BioNTech had an excellent safety profile and remarkably high efficacy (100%) in teenagers. The original study included patients ≥16 years of age and further study was needed for an even younger population that needed to go back to school.  Same as in December 2020, NEJM was the magazine chosen to publish